NeurogesX to Present at Lazard Capital Markets Healthcare Conference

SAN MATEO, Calif., Nov. 26 /PRNewswire-FirstCall/ -- NeurogesX, Inc. , a biopharmaceutical company focused on developing novel pain management therapies, announced today that it is scheduled to present on Wednesday, November 28, 2007 at the Lazard Capital Markets Healthcare Conference in New York City. Anthony DiTonno, President and Chief Executive Officer, will be presenting and Stephen Ghiglieri, Chief Financial Officer, will be available to respond to questions during the break out session.

Event: Lazard Capital Markets Healthcare Conference Date: Wednesday, November 28, 2007 Time: 3:00 p.m. ET Place: New York Palace Hotel, New York

An audio Web cast of the Company's presentations will be available by going to the investor relations section of NeurogesX' Web site at http://www.neurogesx.com/. A replay of the presentation will be available for 15 days.

About NeurogesX, Inc.

NeurogesX is a biopharmaceutical company focused on developing novel pain management therapies. Its initial focus is on chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic neuropathy. NeurogesX' late stage product portfolio is led by its product candidate NGX- 4010, a dermal patch designed to manage pain associated with peripheral neuropathic pain conditions, that the company believes offers significant advantages over other pain therapies. Three Phase 3 clinical trials with NGX- 4010 have been completed and have met their primary endpoints, two in PHN and one in painful HIV-DSP.

Safe Harbor Statement

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include, but are not limited to, the timing of presentations by NeurogesX and the expected benefits of NeurogesX' potential products, including its lead product candidate NGX-4010. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, past results of clinical trials may not be indicative of future clinical trials results; NeurogesX' product candidate may have unexpected adverse side effects or inadequate therapeutic efficacy; positive results in clinical trials may not be sufficient to obtain FDA or European regulatory approval; physician or patient reluctance to use NGX-4010, if approved, or the inability of physicians to obtain sufficient reimbursement for such procedures; potential alternative therapies; maintaining adequate patent or trade secret protection without violating the intellectual property rights of others; and other difficulties or delays in clinical development, obtaining regulatory approval, market acceptance and commercialization of NGX- 4010 and the advantages of NGX-4010 over other pain therapies. For further information regarding these and other risks related to NeurogesX' business, investors should consult NeurogesX' filings with the Securities and Exchange Commission.

NeurogesX Stephen Ghiglieri (650) 358-3310 sghiglieri@neurogesx.com The Ruth Group Investors / Media Stephanie Carrington / Jason Rando (646) 536-7017 / 7025 scarrington@theruthgroup.com jrando@theruthgroup.com

NeurogesX, Inc.

CONTACT: Stephen Ghiglieri, NeurogesX, 1-650-358-3310,
sghiglieri@neurogesx.com; or Investors, Stephanie Carrington, 1-646-536-7017,
scarrington@theruthgroup.com, or Media, Jason Rando, 1-646-536-7025,
jrando@theruthgroup.com, both of The Ruth Group

Web site: http://www.neurogesx.com/